Allergy and Immunology Clinic, University of Health Sciences Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.
Department of Dermatology, Koç University School of Medicine, Istanbul, Turkey.
Libyan J Med. 2024 Dec 31;19(1):2420483. doi: 10.1080/19932820.2024.2420483. Epub 2024 Oct 28.
Biomarkers that could reliably anticipate the effectiveness of antihistamines and omalizumab in treating chronic spontaneous urticaria (CSU) have not been conclusively identified. Our objective was to examine how eosinophilic cationic protein (ECP), tryptase, D-dimer, and total Immunoglobulin E (IgE) impact the response to antihistamine and omalizumab treatments in individuals with CSU.
In this cross-sectional retrospective study, CSU patients that had undergone treatment with either antihistamines or omalizumab for a minimum of 12 weeks between 2015 and 2021 at an Allergy and Immunology Department were analyzed. Several demographic and laboratory parameters including eosinophil counts, mean platelet volüme (MPV), sedimentation, C-reactive protein (CRP), antinuclear antibodies (ANA) and Anti-thyroperoxidase (Anti-TPO) and total IgE, tryptase, ECP and D-dimer were retrived from patient files. The association of these biomarkers with Urticaria Control Test (UCT) and the effect of these biomarkers on treatment response were evaluated. Treatment response was assessed using the UCT, with a score of UCT ≥ 12 indicating a responder and UCT < 12 indicating a non responder.
The patients in the omalizumab group were older, had a longer disease duration and had worse urticaria control (lower baseline UCT scores). 421 patients were treated with antihistamines and 88 patients were treated with omalizumab. ECP was found to be inversely correlated with baseline UCT ( < 0.001 r=-0.268). ECP and D-dimer levels of non-responder patients in the antihistamine group were significantly higher than in responder patients (ECP: 49 ng/mL vs 28.1 ng/mL, < 0.001) (D-dimer: 0.60 mg/L vs 0.30 mg/L, < 0.001), while there were no significant difference in terms of tryptase and total IgE. These four biomarkers were similar, in omalizumab responders and non responders.
In this study with CSU, we looked at predictors of responses to treatments. ECP can serve as a marker of poor urticaria control and may predict antihistamine refractoriness along with D-dimer.
目前尚未明确能够可靠预测抗组胺药和奥马珠单抗治疗慢性自发性荨麻疹(CSU)疗效的生物标志物。我们的目的是研究嗜酸性阳离子蛋白(ECP)、类胰蛋白酶、D-二聚体和总免疫球蛋白 E(IgE)如何影响 CSU 患者对抗组胺药和奥马珠单抗治疗的反应。
本横断面回顾性研究分析了 2015 年至 2021 年期间在过敏和免疫科接受至少 12 周抗组胺药或奥马珠单抗治疗的 CSU 患者。从患者档案中检索了包括嗜酸性粒细胞计数、平均血小板体积(MPV)、沉降率、C 反应蛋白(CRP)、抗核抗体(ANA)和抗甲状腺过氧化物酶(Anti-TPO)以及总 IgE、类胰蛋白酶、ECP 和 D-二聚体在内的多项人口统计学和实验室参数。评估了这些生物标志物与荨麻疹控制测试(UCT)的相关性以及这些生物标志物对治疗反应的影响。使用 UCT 评估治疗反应,UCT 评分≥12 表示应答者,UCT<12 表示无应答者。
奥马珠单抗组患者年龄较大,疾病持续时间较长,荨麻疹控制较差(基础 UCT 评分较低)。421 例患者接受抗组胺药治疗,88 例患者接受奥马珠单抗治疗。ECP 与基础 UCT 呈负相关(<0.001 r=-0.268)。抗组胺药组无应答者的 ECP 和 D-二聚体水平明显高于应答者(ECP:49ng/mL 比 28.1ng/mL,<0.001)(D-二聚体:0.60mg/L 比 0.30mg/L,<0.001),而类胰蛋白酶和总 IgE 无显著差异。奥马珠单抗组的应答者和无应答者这四个生物标志物相似。
在这项 CSU 研究中,我们研究了治疗反应的预测因素。ECP 可作为荨麻疹控制不良的标志物,可能与 D-二聚体一起预测抗组胺药耐药。